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Nucleosides represent a major chemotherapeutic class for treating cancer, however their limitations in
terms of cellular uptake, nucleoside kinase-mediated activation and catabolism are well-documented.
The monophosphate pro-nucleotides known as ProTides represents a powerful strategy for bypassing
the dependence on active transport and nucleoside kinase-mediated activation. Herein, we report the
structural tuning of BVdU ProTides. Forty six phosphoramidates were prepared and biologically evaluated
against three different cancer cell lines; murine leukemia (L1210), human CD4+ T-lymphocyte (CEM) and
human cervical carcinoma (HeLa). Twenty-fold potency enhancement compared to BVdU was achieved
against L1210 cells. Interestingly, a number of ProTides showed low micromolar activity against CEM
and HeLa cells compared to the inactive parent BVdU. The ProTides showed poor, if any measurable tox-
icity to non-tumourigenic human lung fibroblast cell cultures. Separation of four pairs of the diastereoiso-
meric mixtures and comparison of their spectral properties, biological activities and enzymatic activation
rate is reported.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Over the past 40 years, nucleoside analogues have been estab-
lished as first-line antiviral and anticancer agents. In most cases
phosphorylation is required to convert the nucleoside analogues
to the corresponding 5’-monophosphates and subsequently to
the triphosphates [1–3]. However, this three-step intracellular
conversion is often inefficient in the intact cells being rate-limited
by the initial phosphorylation step; furthermore, lower, or lack of
expression of nucleoside kinases often leads to emergence of resis-
tance to the nucleoside analogue treatment [1,2]. Unfortunately,
nucleotides cannot be considered as therapeutic agents because
of their polar nature, their impermeability through the cell mem-
brane and their dephosphorylation in extracellular fluids. There-
fore, considerable efforts have focused on monophosphate
prodrugs that carry little or no charge to mask the negative charge
of the phosphate group of the nucleotides, with various chemically
or enzymatically cleavable moieties once the compound is trans-
ported into the cell [2,3]. Among all reported pro-nucleotide
approaches, the class of aryl phosphoramidate nucleosides knownas ProTides, pioneered by McGuigan and co-workers, has been pro-
ven to enhance the activity of parent nucleosides by improving
intracellular transport and/or by bypassing the rate-limiting
monophosphorylation step. These improvements serve to eventu-
ally increase the formation rate of intracellular nucleoside triphos-
phate [4]. Proof-of-principle in patients is demonstrated with two
FDA-approved therapeutic antiviral agents, Sofosbuvir used for
hepatitis C virus treatment and tenofovir alafenamide used for
human immunodeficiency virus treatment. Additionally, there
are more ProTides in the pipelines of several academic groups
and pharmaceutical companies undergoing preclinical and clinical
studies for the treatment of viral infections and cancer [2]. The
gemcitabine ProTide known as NUC-1031 represents an example
of an anticancer ProTide currently in Phase 2 clinical trial [5].
Brivudine, (E)-5-(2-bromovinyl)-20-deoxyuridine, (BVdU) Fig. 1
is a potent inhibitor of herpes simplex virus type 1 (HSV-1) and
varicella–zoster virus (VZV). The application of ProTide technology
on the BVdU scaffold led to less potent derivatives compared to the
parent agent against VZV in cell culture models [6]. This was inter-
preted as corresponding to poor intracellular delivery of BVdU
monophosphate (BVdUMP), rapid degradation to BVdU or poor
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Fig. 1. Chemical structure of the BVdU and its ProTide derivative NB1011.
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[6]. However, NewBiotics Inc. had independently prepared NB1011
(Thymectacin) which has recently entered Phase I/II clinical trials
for the treatment of colon cancer [7,8]. Further studies on
NB1011 revealed that it is selectively toxic to tumour cells express-
ing elevated levels of thymidylate synthase (TS), a key enzyme in
DNA synthesis [9].
Some SAR optimisation of NB1011 was previously reported
against human breast (MCF-7, MDA MB 231), prostate (PC3), colon
(HT115) and bladder (T24) cancer cell lines [10]. In this work we
report the synthesis and biological evaluation of an extensive ser-
ies of BVdU phosphoramidate derivatives. The tuning of the parent
structure involved combined modifications of the amino acid ester,
the aromatic masking group on the phosphate moiety and the 5-
position of the BVdU nucleoside base. We have synthesized 46
BVdU phosphoramidate derivatives 8–53 possessing improved
cytotoxic activity against three tumour cell lines; murine leukemia
(L1210), human CD4+ T-lymphocyte (CEM) and human cervical car-
cinoma (HeLa). Moreover, separation of four phosphorus centre
diastereoisomeric pairs was successfully achieved and provided
useful comparative insights. Applying the previously reported
computational and NMR studies, the absolute stereochemistry of
the phosphorus centre of some of these diastereoisomers has been
predicted.
BVdU is prepared from 5-iodo-20-deoxyuridine 1, which was
used to prepare the carboxymethyl ester derivative, 2 via Heck
reaction with methyl acrylate in the presence of palladium acetate.
Hydrolysis of 2 was carried out using NaOH followed by acidifica-
tion to get the carboxylic acid derivative 3, which was treated with
N-bromosuccinimide (NBS) to give BVdU [11], Scheme 1.
The target BVdU ProTides were all prepared using the exten-
sively described phosphorochloridate chemistry [12,13]. The phe-
nyl phosphorodichloridate 4a was used to introduce the phenolic
aromatic masking unit of the ProTide. For the naphthyl analogues,
1-naphthol was reacted with phosphoryl chloride to give the
required dichloridate 4b, Scheme 2. The second component of
the ProTide motif is an amino acid ester (general formula, 5), if
not commercially available, was prepared by esterification of the
appropriate amino acids using standard methods [14]. The ary-
laminoacyl phosphorochloridate (general formula, 6), were pre-
pared by reacting the aryl phosphorodichloridate 4a or 4b with1              2 
Scheme 1. Synthesis of BVdU; Reagents and conditions; i) Pdthe amino acid ester 5, Scheme 2. The formation of the key phos-
phorochloridate was monitored by 31P NMR. Next, the arylaminoa-
cyl phosphorochloridate 6 was reacted with either BVdU or its
carboxy methyl ester precursor 2 in the presence of 1-methylimi-
dazole (NMI), Scheme 2. Overnight reactions at ambient tempera-
ture generated crude materials that were purified by column
chromatography to provide low to moderate yields typical of pre-
vious phosphoramidate ProTide syntheses (3.4–28%) [15]. Each of
the phosphoramidate compounds was generated as a pair of
diastereoisomers at the phosphate center, in roughly 1:1 ratio, as
revealed by the two closely spaced peaks in the 31P NMR spectrum.
It has been reported before that the biological activity of phos-
phoramidates can be dependent on the configuration of the phos-
phorus centre [16,17]. Single phosphorus centre diastereoisomers
were separated from their corresponding racemic mixtures of com-
pounds (35, 36, 47 and 49) using a combination of gradient column
chromatography and preparative thin liquid chromatography.
Obtaining four pairs of fast eluting (f) and slow eluting (s)
diastereoisomers; (35f/35s, 36f/36s, 47f/47s and 49f/49s, respec-
tively), offered the opportunity to compare their spectroscopic,
anti-proliferative and enzymatic activation rate profiles. Fig. 2A,
shows the 31P NMR of the diastereoisomeric mixture of 36 and that
of its single diastereoisomer components separated (36s and 36f),
Fig. 2B and C, respectively. It is noteworthy that in the case of pro-
line-based ProTides (39 and 51), we obtained single P diastereoiso-
mers, however the reasons behind this observed stereoselectivity
still need to be investigated.
A comparison between the 1H NMR spectra of the diastereoiso-
meric pair (49s, 49f) revealed a characteristic pattern difference of
the benzylic methylene protons, Fig. 3. For the 49f diastereoisomer,
the two protons display a singlet signal, Fig. 3A, while the 49s
diastereoisomer shows a double doublet signal, Fig. 3B. Similar
findings were reported before for a partially separated racemic
mixture of another BVdU ProTide analogue using preparative HPLC
and were previously explained through conformational studies
[10]. The three aromatic rings (nucleoside base, benzyl ester and
naphthyl) are stacked in p-p interactions in the case of the Sp
diastereoisomer. This imparts relative rigidity of this conformation
and justifies the observed non-equivalent double of doublet split-
ting NMR pattern of the benzylic methylene hydrogens. On the
other hand, the Rp counterpart does not show such interaction
among the aromatic rings, resulting in the greater flexibility of
the benzylic methylene group reducing the magnetic differences
between the two protons and hence, they appear as a singlet sig-
nal. Therefore, by combining the NMR and the conformational data,
we can propose the Rp configuration to the fast-eluting
diastereoisomer 49f and, consequently, the Sp absolute configura-
tion to the slow-eluting diastereoisomer 49s.
ProTides 8–53 described above were evaluated for their cyto-
static activity against a panel of three established tumour cell lines
in vitro: L1210 (murine leukemia), CEM (human CD4+ T-lympho-
cyte), and HeLa (human cervix). In each case a thymidine kinase-
deficient (TK) mutant of the parent cell line is included to probe
the effect of TK deficiency on the cytostatic activity of the test com-3                             BVdU
(OAc)2, PPh3, Me acrylate, ii) NaOH, HCl, iii) NBS, K2CO3.
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Fig. 2. A) 31P NMR of the racemic mixture 36, B) slow eluting diastereoisomer, 36s, C) fast eluting diastereoisomer 36f.
Fig. 3. 1H NMR spectra of the benzylic methylene protons (CH2) of the isolated diastereoisomers; (a) 49f, (b) 49s.
5620 S. Kandil et al. / Bioorganic & Medicinal Chemistry Letters 26 (2016) 5618–5623pounds and the degree to which the ProTides could bypass this
dependence. The murine L1210 cell line was included because
these tumour cells can be used in a mouse tumour model. Also, a
normal human non-tumourigenic primary monolayer cell line
(lung fibroblast HEL cells) is included for comparative purposes,
and BVdU as a positive parental drug control, Table 1. For the mur-
ine leukemia cell line (L1210), alanine-based ProTides were
amongst the most active compounds with compound 23 (L-alani-
nyl benzyl ester naphthoxy phosphoramidate, IC50 = 1.8 lM)
showing 20-fold increase in potency compared to BVdU (IC50 = 38 -
lM). Interestingly, while BVdU itself does not show any notewor-
thy anti-proliferative activity against the human T-lymphocyte cell
line (CEM) (IC50 > 100 lM), most of its phosphoramidate deriva-
tives showed a greatly enhanced activity with compound 37 (L-
phenylalaninyl ethyl ester naphthoxy phosphoramidate,IC50 = 4.8 lM) being the most active. While BVdU is poorly cyto-
static against the human cervical carcinoma (HeLa) (IC50 = 160 -
lM), compounds 33 (L-valinyl cyclohexyl ester naphthoxy
phosphoramidate, IC50 = 7.2 lM) and 36 (L-tryptophanyl ethyl
ester naphthoxy phosphoramidate, IC50 = 7.8 lM) were found to
boost the antiproliferative activity significantly. Interestingly,
BVdU and its phosphoramidate ProTide derivatives generally
showed poor, if any cytotoxicity against the human lung fibroblast
cell cultures displaying minimal cytotoxic concentration (MCC)
values of P100 lM in the vast majority of the test compounds,
Table 1. These findings point to a considerable extent of selectivity
of the synthesised ProTides, which is potentially beneficial from a
drug development viewpoint.
It has been noticed before that BVdU, in contrast to most other
thymine-based nucleoside analogues, often shows an increased
Table 1
Inhibitory effects of BVdU ProTides on the proliferation of murine leukemia (L1210, L1210/TK-), human CD4+ T-lymphocyte (CEM, CEM/TK-) and human cervical carcinoma (HeLa,
HeLa/TK) cells, and their toxicity against human non-tumourigenic lung fibroblast (HEL) cultures.
No. R Ar Ester AA IC50 (lM) MCCa
L1210/0 L1210/TK Cem/0 Cem/TK HeLa HeLa/TK HEL
8 Br Ph Bn Ala 2.8 ± 0.3 0.35 ± 0.1 36 ± 1.0 32 ± 2.0 38 ± 2.0 3.1 ± 1.7 P100
9 Br Ph Et Ala 17 ± 5.0 2.0 ± 1.4 32 ± 11.0 21 ± 0.0 48 ± 7.0 9.6 ± 1.8 100
10 Br Ph Me Trp 13.2 ± 0.3 6.7 ± 0.6 24 ± 0.6 16 ± 1.0 33 ± 6.0 1.2 ± 0.0 100
11 Br Ph Et Trp 18 ± 1.0 4.2 ± 0.2 14 ± 6.0 14 ± 2.0 18 ± 3.0 2.7 ± 0.1 100
12 Br Ph Me Phe 32 ± 2.0 6.2 ± 0.7 23 ± 2.0 6.7 ± 3.2 34 ± 2.0 2.8 ± 1.8 >100
13 Br Ph Et Phe 30 ± 3.0 5.6 ± 0.7 23 ± 4.0 9.5 ± 2.3 40 ± 4.0 3.8 ± 2.8 >100
14 Br Ph cHex Val 9.3 ± 0.2 10 ± 0.0 8.6 ± 1.1 10 ± 0.0 12 ± 0.0 7.4 ± 0.4 >100
15 Br Ph Et Tyr 48 ± 5.0 26 ± 4.0 >100 >100 47 ± 9.0 8.2 ± 2.2 >100
16 Br Ph cHex Ala 2.6 ± 0.2 1.5 ± 0.0 15 ± 4.0 25 ± 5.0 16 ± 0.0 6.5 ± 1.7 >100
17 COOMe Ph Me Ala 14 ± 0.0 15 ± 2.0 34 ± 6.0 47 ± 1.0 10 ± 0.0 6.1 ± 1.0 >100
18 COOMe Ph Et Phe 67 ± 13.0 57 ± 6.0 55 ± 2.0 24 ± 11.0 80 ± 10.0 35 ± 1.0 >100
19 COOMe Ph Me Phe >100 >100 >100 69 ± 43.0 >100 66 ± 31.0 >100
20 COOMe Ph cHex Val 75 ± 8.0 79 ± 3.0 69 ± 8.0 81 ± 7.0 P 100 38 ± 7.0 >100
21 COOMe Ph Bn Ala 4.0 ± 2.3 36 ± 5.0 19 ± 2.0 51 ± 6.0 32 ± 5.0 42 ± 9.0 >100
22 Br Nap NeoPnt Ala 15 ± 2.0 0.89 ± 0.08 13 ± 1.0 13 ± 4.0 32 ± 13.0 4.7 ± 1.3 100
23 Br Nap Bn Ala 1.8 ± 0.0 0.24 ± 0.3 9.3 ± 3.9 5.4 ± 0.9 33 ± 17.0 1.1 ± 0.3 P100
24 Br Nap cHex Ala 9.2 ± 3.7 2.9 ± 0.0 6.1 ± 0.2 5.8 ± 0.6 32 ± 20.0 3.0 ± 1.6 20
25 Br Nap Et Ala 8.0 ± 5.2 0.47 ± 0.2 28 ± 12.0 16 ± 3.0 84 ± 13.0 4.7 ± 0.0 >100
26 Br Nap iPr Ala 18 ± 1.0 1.6 ± 0.2 14 ± 4.0 15 ± 1.0 21 ± 1.0 5.5 ± 0.3 100
27 Br Nap Bn Met P 250 167 ± 69.0 >250 >250 >250 22.0 ± 9.0 P20
28 Br Nap Bn Val 7.1 ± 2.3 10 ± 4.0 6.0 ± 0.1 5.2 ± 0.3 12 ± 5.0 3.6 ± 0.3 10
29 Br Nap Bn Pro 15 ± 1.0 16 ± 1.0 9.9 ± 0.9 12 ± 0.0 23 ± 2.0 5.2 ± 3.5 P4
30 Br Nap 2-Bu Ala 17 ± 2.0 3.1 ± 0.5 15 ± 2.0 15 ± 3.0 23 ± 1.0 4.3 ± 2.4 P100
31 Br Nap Bn Gly 18 ± 3.0 3.9 ± 0.1 18 ± 2.0 19 ± 1.0 36 ± 19.0 1.1 ± 0.6 100
32 Br Nap Bn D-Ala 21 ± 3.0 19 ± 1.0 17 ± 0.0 18 ± 3.0 31 ± 8.0 7.7 ± 5.0 P100
33 Br Nap cHex Val 8.3 ± 0.2 8.8 ± 0.1 7.4 ± 1.3 8.4 ± 1.5 7.2 ± 0.2 5.0 ± 0.9 P100
34 Br Nap Et Val 16 ± 3.0 16 ± 3.0 8.4 ± 1.8 9.2 ± 2.3 27 ± 5.0 7.2 ± 1.1 P100
35f Br Nap Me Trp 7.7 ± 0.9 2.4 ± 0.3 9.6 ± 1.7 8.0 ± 0.4 26 ± 14.0 3.2 ± 1.9 100
35s 40 ± 2.0 28 ± 9.0 39 ± 5.0 26 ± 2.0 43 ± 3.0 17 ± 7.0 100
36 8.3 ± 0.6 4.0 ± 0.9 7.1 ± 0.5 6.1 ± 1.1 7.8 ± 0.7 6.0 ± 1.4 –
36 f Br Nap Et Trp 8.7 ± 0.7 2.5 ± 0.1 9.8 ± 1.5 7.6 ± 1.6 3.9 ± 1.3 2.3 ± 1.2 P100
36s 8.2 ± 0.3 7.0 ± 0.5 7.8 ± 0.6 5.8 ± 1.3 8.2 ± 0.1 3.1 ± 0.4 35
37 Br Nap Et Phe 7.5 ± 0.4 8.2 ± 0.1 4.8 ± 1.0 4.6 ± 1.0 18 ± 3.0 2.8 ± 0.4 100
38 Br Nap Me Phe 18 ± 1.0 14 ± 0.0 13 ± 8.0 6.3 ± 1.1 73 ± 0.0 1.8 ± 0.8 100
39 Br Nap Et Pro 27 ± 7.0 14 ± 6.0 11 ± 1.0 9.5 ± 1.4 30 ± 3.0 6.4 ± 1.0 >100
40 Br Nap Et OMeTyr 19 ± 8.0 6.8 ± 2.1 13 ± 1.0 6.6 ± 2.8 32 ± 2.0 6.1 ± 1.2 100
41 Br Nap n-Pnt Val 23 ± 5.0 12 ± 3.0 29 ± 1.0 12 ± 2.0 33 ± 6.0 10 ± 0.0 >100
42 Br Nap n-Pnt Phe 13 ± 1.0 9.6 ± 0.4 17 ± 2.0 10 ± 0.0 38 ± 7.0 9.3 ± 0.0 100
43 Br Nap Et Tyr 8.4 ± 0.3 6.9 ± 0.4 9.6 ± 0.1 8.2 ± 0.5 38 ± 1.0 1.7 ± 0.8 >100
44 Br Nap Et Met 26 ± 0.0 8.3 ± 0.0 19 ± 9.0 12 ± 4.0 36 ± 0.0 11 ± 3.0 >100
45 Br Nap cHex Gly 15 ± 5.0 6.9 ± 0.5 11 ± 4.0 9.5 ± 0.2 29 ± 10.0 6.3 ± 2.1 100
46 Br Nap Neo-pnt DMG 9.2 ± 1.2 3.0 ± 1.7 10 ± 2.0 8.6 ± 0.0 25 ± 6.0 7.4 ± 0.3 P20
47f COOMe Nap Et Trp 8.8 ± 0.0 8.9 ± 0.9 11 ± 0.0 6.2 ± 2.3 36 ± 4.0 19 ± 13.0 >100
47s 11 ± 1.0 14 ± 0.0 11 ± 0.0 8.9 ± 0.8 34 ± 1.0 32 ± 7.0 100
48 COOMe Nap Et Val 56 ± 2.0 40 ± 3.0 49 ± 3.0 47 ± 1.0 79 ± 7.0 15 ± 10.0 >100
49 42 ± 5.0 32 ± 2.0 35 ± 8.0 46 ± 4.0 57 ± 0.0 26 ± 10.0 >100
49f COOMe Nap Bn Ala 32 ± 6.0 22 ± 9.0 27 ± 2.0 20 ± 10.0 37 ± 1.0 29 ± 9.0 100
49s 35 ± 6.0 21 ± 8.0 29 ± 3.0 32 ± 8.0 37 ± 4.0 11 ± 6.0 100
50 COOMe Nap cHex Val 16 ± 1.0 16 ± 7.0 10 ± 1.0 8.1 ± 1.7 29 ± 2.0 11 ± 2.0 >100
51 COOMe Nap Et Pro 54 ± 4.0 46 ± 3.0 38 ± 2.0 42 ± 1.0 P 100 40 ± 2.0 >100
52 COOMe Nap n-Pnt Phe 10 ± 0.0 12 ± 1.0 12 ± 3.0 8.1 ± 1.5 33 ± 6.0 9.7 ± 0.2 >100
53 COOMe Nap Et Met 26 ± 3.0 50 ± 7.0 52 ± 8.0 58 ± 8.0 62 ± 11.0 35 ± 9.0 >100
BVdU 38 ± 4.0 9.6 ± 2.8 >100 100 160 ± 21.0 0.20 ± 0.16 –
a MCC or minimal cytotoxic concentration in (lM) required to afford a microscopically visible alteration of cell morphology.
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lines. The molecular/biochemical basis for this phenomenon is still
unclear [18]. Here, a pronounced increase of cytostatic activity was
also observed for several BVdU ProTides (i.e. 8, 16, 21 for L1210
and the majority of compounds for CEM and HeLa). These observa-
tions are of particular interest since certain forms of drug resis-
tance of cancer cells have been reported to be caused by
thymidine kinase deficiency (i.e. drug resistance against 5-FdUrd-
and 5-trifluoromethyl-dUrd-treated cancers) [19,20]. It would
therefore be reasonable to suggest the use of such BVdU ProTides
to treat tumours that became refractory to FdUrd/CF3dUrd
treatment.All compounds 8–53, were evaluated as mixtures of two phos-
phate diastereoisomers (Rp and Sp in 1:1 ratio). Interestingly, we
were able to separate four pairs of diastereoisomers, 35f/35s,
36f/36s, 47f/47s and 49f/49s, which offered the opportunity to
compare their relative biological activity, Table 1. It could be con-
cluded that in general, the fast eluting diastereoisomer 35f showed
a relatively better cytostatic activity across the three cell lines than
its slow eluting diastereoisomer 35s. Apart from 35f/35s, the other
three pairs of diastereoisomers, 36f/36s, 47f/47s and 49f/49s, dis-
played very similar activity profiles across the three cell lines. In
two cases, 36 and 49, the activity of the parent racemic mixture
(1:1 ratio) and that of its single diastereoisomeric components
Scheme 3. Proposed activation pathway of phosphoramidate 35; i) esterase or carboxypeptidase-type enzyme, ii) and iii) spontaneous, iv) phosphoramidase-type enzyme.
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the anti-proliferative activity were very similar, Table 1.
The side products from the catabolic conversion of the BVdU
ProTides to BVdU-MP are amino acids, and phenol or naphthol.
Whereas the release of naturally occurring amino acids should
not be a matter of concern in terms of potential side-effects, the
release of naphthol or phenol might be. However, it should be
noted there are currently two ProTide derivatives approved for
clinical use (i.e. TAF, or tenofovir alafenamide [21,22] and Sofosbu-
vir [2]) that release phenol upon conversion to the parent com-Fig. 4. 31P NMR spectra of ProTide 35f (A) and ProTide 35s (B) over time (every 7 min)
signals of different metabolites.pound without measurable toxic side-effects. Also, given the
increased activity of some of the BVdU prodrugs against TK-defi-
cient tumour cell lines, the use of BVdU ProTides may perhaps be
more efficient in suppression of TK- based resistance development.
Generally, the activity profiles suggested that our library of phos-
phoramidates were able to release the nucleoside monophosphate
within intact cells and afford pronounced cytostatic activity in
both the wild-type and TK- cancer cell lines, as shown in Table 1.
Nucleoside analogues are challenged by numerous inherent and
acquired cancer resistance mechanisms that can significantly limitafter treatment with carboxypeptidase Y (5 mg in acetone-D/Trizma) showing the
S. Kandil et al. / Bioorganic & Medicinal Chemistry Letters 26 (2016) 5618–5623 5623their effectiveness. ProTides are specifically designed to overcome
some key cancer resistance pathways and thereby achieve a supe-
rior antineoplastic effect. To exert their anticancer activity, the Pro-
Tides are metabolised to release the free nucleoside
monophosphate form, which will then generate the corresponding
active forms, di- and/or triphosphates. The proposed intracellular
activation route of the ProTides has been described for other Pro-
Tide families [23] and is exemplified by compound 35 in Scheme 3.
The proposed mechanism of activation of the ProTides involves a
first enzymatic activation step (i) mediated by a carboxypepti-
dase-type enzyme that hydrolyses the ester of the aminoacyl moi-
ety to produce the intermediate A. Next, a spontaneous cyclization
(ii) displacing the aryl moiety via an internal nucleophilic attack of
the carboxylate residue on the phosphorus center to yield B. In a
third step (iii), the unstable ring is hydrolysed to release the inter-
mediate C. The last step (iv) involves a phosphoramidase-type
enzyme, which cleaves-off the amino acid to generate the corre-
sponding nucleoside monophosphate D, Scheme 3. This assay
was designed to verify whether an enzymatic cleavage of the ester
motif would be sufficient to trigger the first steps of the activation
route and generate the intermediate C [24].
To probe the difference between the P diastereoisomer activa-
tion rate, Scheme 3, an enzymatic study using carboxypeptidase
Y while monitoring the conversion by 31P NMR was performed.
Each diastereoisomer of compound 35; (35f and 35s) was dissolved
in acetone-d6 in the presence of Trizma buffer (pH 7.6) and treated
with carboxypeptidase Y to monitor the metabolic conversion of
the ProTide using 31P NMR spectroscopy over time, Fig. 4. In the
case of compound 35f, the experiment showed the hydrolysis of
the starting material 35f (dP = 4.19) to the intermediate type A
(dP = 5.08), which is then processed to a compound of type C
(dP = 7.09) through the putative intermediate B, Fig. 4A. Interest-
ingly, in the case of compound 35s, the enzymatic study showed
a relatively faster hydrolysis rate of 35s (dP = 4.13), which is con-
verted directly to compound of type C (dP = 7.08), Fig. 4B. These
findings demonstrate that phosphoramidate diastereoisomers are
processed at different rates by carboxypeptidase-type enzymes.
In an attempt to better understand the difference in the enzy-
matic activation rate of both diastereoisomers of compound 35 in
the enzymatic study, a molecular modelling simulation using the
crystal structure of the carboxypeptidase Y (PDB; 1YSC) [25,26]
was performed, Fig. S4 (supporting information, computational
study section).
In summary, a series of forty six BVdU ProTides has been syn-
thesised and have been biologically evaluated together with the
parent BVdU nucleoside for their cytostatic activity in vitro
against three different cancer cell lines; murine leukemia
(L1210), human T-lymphocyte (CEM) and human cervix carci-
noma (HeLa) and for toxicity against human non-tumourigenic
lung fibroblast (HEL) cell cultures. ProTide 23 showed twenty-fold
better cytostatic activity than the parent BVdU against the L1210
cell line. Low micromolar activity against the CEM and HeLa
tumour cell lines compared to inactive parent BVdU nucleoside
was observed with a number of our ProTides. The anti-prolifera-
tive activity was retained or even enhanced against thymidine
kinase-deficient cancer cell lines. Poor, if any cytotoxic activity
was observed in HEL cell cultures pointing to a considerable
degree of selectivity. Separation of four pairs of P diastereoiso-
mers and the comparison of some spectral properties, anticancer
cell activity and enzymatic activation features is described.
Molecular modeling studies were conducted in an attempt to
explain some of our findings.
Finally, we have demonstrated that the application of the phos-
phoramidate approach to brivudine (BVdU) results in an extensive
source of potential anticancer agents.Acknowledgements
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